Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
OptiTROP-Lung03
SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
- NCT05631262 ↗
- Active, not recruiting
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Focused
We haven't built an HCP commentary report on OptiTROP-Lung03 (SKB264 and docetaxel in Selected Subjects With Advanced Solid Tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on OptiTROP-Lung03 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 7 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Selected Subjects With Advanced Solid Tumors
- Interventions
- SKB264; Docetaxel
- Arms
- SKB264 (Cohort 1) · Experimental
- SKB264 (Cohort 2) · Experimental
- SKB264 (Cohort 3) · Experimental
- SKB264 (Cohort 4) · Experimental
- SKB264 (Cohort 5) · Experimental
- Part II Test group · Experimental
- Part II Control group · Active comparator
- Enrollment
- 321
- Primary outcomes
- Objective Response Rate (ORR)
- Incidence and severity of adverse events (AEs)
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Start
- Nov 30, 2022
- Primary completion
- Dec 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05631262 · updated May 8, 2026
Publications
linked from the registry- Fang W, Li X, Wang Q, Meng X, Zheng W, Sun L, Yao W, Zhuang W, Fan Y, Zhuo M, Luo Y, Zhang Z, Song X, Yang R, Yang J, Jin X, Diao Y, Ge J, Zhang L. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial. BMJ. 2025 Jun 5;389:e085680. doi: 10.1136/bmj-2025-085680. PubMed 40473437
- Zhao S, Cheng Y, Wang Q, Li X, Liao J, Rodon J, Meng X, Luo Y, Chen Z, Wang W, Yi T, Li Y, Yin Y, Xu H, Yu G, Mi Y, Fan Y, Wainberg ZA, Wang X, Su C, Yu Q, Lai S, Sun L, Zhuang W, Wang X, Yang J, Li Y, Ge J, Li J, Zhang L, Fang W. Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials. Nat Med. 2025 Jun;31(6):1976-1986. doi: 10.1038/s41591-025-03638-2. Epub 2025 Apr 10. PubMed 40210967